ArticleInternational journal of preventive medicine2013
The effects of gluten-free diet on hypertransaminasemia in patients with celiac disease.
Article in International journal of preventive medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- Celiac Disease and Liver Damage: The Gut-Liver Axis Strikes Back (Again)? A Retrospective Analysis in the Light of a Literature Review.Nutrients · 2024Review
- The Effects of Gluten on Weight Gain, Hematological, Biochemical, and Various Endocrinological Parameters.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2024Article
- Intestinal mRNA expression analysis of polarity-related genes identified the discriminatory ability of CRB3 as a diagnostic marker for celiac disease.Immunity, inflammation and disease · 2024Article
- Celiac Disease and Targeting the Molecular Mechanisms of Autoimmunity in COVID Pandemic.International journal of molecular sciences · 2022Review
- C-reactive protein as a possible marker for severity and mortality of COVID-19 infection.Gastroenterology and hepatology from bed to bench · 2021Article
- Gut microbiota, angiotensin-converting enzyme, celiac disease, and risk of COVID-19 infection: a review.Gastroenterology and hepatology from bed to bench · 2021Review
- Liver pathology in children with newly diagnosed celiac disease.Clinical and experimental hepatology · 2019Article
- To screen or not to screen? Celiac antibodies in liver diseases.World journal of gastroenterology · 2017Review
- Celiac disease unmasked by acute severe iron deficiency anemia.Journal of community hospital internal medicine perspectives · 2016Article
- Prevalence of abnormal liver function tests in celiac disease and the effect of a gluten-free diet in the US population.The American journal of gastroenterology · 2015Article
- Estimation of serum iron, serum lipids and serum liver enzymes in celiac disease patients of Saudi Arabia.Pakistan journal of medical sciencesArticle
- Association of Autoimmune Hepatitis and Celiac Disease: Role of Gluten-Free Diet in Reversing Liver Dysfunction.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCeliac disease (CD) is an immune mediated condition that leads to small bowel atrophy and improve with a gluten free diet (GFD). Extra-intestinal manifestations of CD include hypertransaminasemia. In this study, the effects of a GFD on hypertransaminasemia in patients with newly diagnosed CD were studied.
methodsNinety eight new diagnosed consecutive patients with CD 40 males and 58 females) with mean age of 32 ± 17.1 were studied. All patients with CD were treated with a GFD. Patients with hypertransaminasemia, at diagnosis, had a cirrhosis screen performed. Patients with a negative cirrhosis screen were reviewed, 6 months after the introduction of a GFD, and serum levels of liver transaminases were measured again.
resultsNine patients had hypertransaminasemia. One patient was Hepatitis B surface antigen positive and was excluded from this study. The 8 remaining patients had no obvious cause for the hypertransaminasemia. Mean (± SD) of baseline aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were 42.6 ± 16.5 IU/L (range: 16-66 IU/L) and 69.3 ± 9.3 IU/L (range: 52-81 IU/L). Six months after treatment with a GFD, mean AST and ALT levels decreased to 24.5 ± 5.1 IU/L (range: 18-31 IU/L) (P: 0.04) and 24.6 ± 6 IU/L (range: 17-32 IU/L) (P: 0.01), respectively. In 7 patients the hypertransaminasemia, at diagnosis had resolved.
conclusionsThis study provides further evidence that some patients with CD have a reversible hypertransaminasemia that resolves with a GFD.
Indexed as
Identifiers
23930188PMC3733038W1551463500What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.